CCM
BIIB icon

Copernicus Capital Management’s Biogen BIIB Stock Holding History

Copernicus Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-18,000
Closed -$5.7M – 19
2020
Q1 		$5.7M Buy
+18,000
New +$5.46M 6.89% 7
2018
Q2 		– Sell
-33,296
Closed -$9.12M – 20
2018
Q1 		$9.12M Buy
33,296
+14,975
+82% +$4.65M 7.27% 4
2017
Q4 		$5.84M Buy
+18,321
New +$5.88M 4.35% 12

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Copernicus Capital Management's BIIB Position: Q2 2020 in Review

Copernicus Capital Management sold out of Biogen (BIIB) in Q2 2020, closing a stake of 18,000 shares — an estimated $5.7M sold.

Copernicus Capital Management first reported a position in BIIB in Q4 2017 and held it in 3 quarters. The position peaked at $9.12M in Q1 2018. 1,059 funds tracked by Wall St. Rank hold BIIB as of Q2 2020.

  • Copernicus Capital Management reported no remaining Biogen position as of Q2 2020 after selling out during the quarter.
  • Copernicus Capital Management sold 18,000 Biogen shares in Q2 2020, an estimated $5.7M.
  • Copernicus Capital Management first reported a position in Biogen in Q4 2017 and held it in 3 quarters.
  • Copernicus Capital Management's Biogen position peaked at $9.12M in Q1 2018.
  • 1,059 funds tracked by Wall St. Rank held Biogen as of Q2 2020.

Based on Copernicus Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.